抗炎药物在炎症性风湿病中的心脏保护机制与疗效
该叙述性综述评估了秋水仙碱及传统合成改善病情抗风湿药(甲氨蝶呤、羟氯喹、柳氮磺吡啶、来氟米特)在炎症性风湿与肌肉骨骼疾病(RMDs)中的动脉粥样硬化性心血管疾病(ASCVD)保护机制与临床证据。秋水仙碱在已确诊冠心病患者中减少复发性ASCVD事件的随机证据最强;甲氨蝶呤与RA患者心血管事件减少相关,但CIRT试验在无炎症性关节炎患者中为中性。任何csDMARD在主要用于ASCVD预防前,仍需在炎症性RMD人群中进行专门的前瞻性试验。
要点
- 秋水仙碱在已确诊冠心病患者中减少复发性ASCVD事件的随机证据最强。
- 甲磺酸酯与RA患者心血管事件减少相关,但CIRT试验在无炎症性关节炎患者中为中性。
- 羟氯喹有有利的脂质、血糖和抗血栓效应,但尚无确定性心血管结局试验。
核心结论
- 心血管获益在不同药物间差异显著,秋水仙碱在二级预防中最具说服力,甲氨蝶呤在RA中通过控制炎症带来获益。
- 任何csDMARD在主要用于ASCVD预防前,需在炎症性RMD人群中进行专门的前瞻性试验。
研究设计与样本
- 靶向叙述性综述,纳入关键实验研究、随机心血管结局试验、观察性RMD队列和系统综述,优先选择与ASCVD结局和心血管代谢机制直接相关的证据。
主要发现
- 秋水仙碱在已确诊冠心病患者中减少复发性ASCVD事件的随机证据最强,痛风中有支持性观察数据。
- 甲氨蝶呤与RA患者心血管事件减少相关,而CIRT试验在无炎症性关节炎患者中为中性。
- 羟氯喹具有有利的脂质、血糖和抗血栓效应,并在RA和SLE中与较低心血管风险有观察性关联,但无确定性心血管结局试验。
- 柳氮磺吡啶的证据有限且为观察性,来氟米特的人体数据相互矛盾。
临床怎么用
- 秋水仙碱在已确诊冠心病患者中可用于减少复发性ASCVD事件。
- 甲氨蝶呤在RA中通过控制炎症可能带来心血管获益,但不应仅用于ASCVD预防。
- 羟氯喹在RA和SLE中与较低心血管风险有观察性关联,但缺乏确定性结局试验证据。
- 柳氮磺吡啶和来氟米特的心血管保护证据不足或矛盾,不推荐用于ASCVD预防。
局限性
- 叙述性综述,非系统评价,证据选择可能存在偏倚。
- 缺乏在炎症性RMD人群中专门评估ASCVD结局的前瞻性随机试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic systemic inflammation contributes to the excess risk of atherosclerotic cardiovascular disease (ASCVD) in inflammatory rheumatic and musculoskeletal diseases (RMDs), raising the possibility that anti-inflammatory treatment may modify vascular risk. This review sought to critically review the mechanistic and clinical evidence for atheroprotection with colchicine and the commonly used conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) methotrexate, hydroxychloroquine, sulfasalazine and leflunomide. We performed a targeted narrative review of key experimental studies, randomized cardiovascular outcome trials, observational RMD cohorts and systematic reviews, prioritizing evidence directly relevant to ASCVD outcomes and cardiometabolic mechanisms. Colchicine has the strongest randomized evidence for reducing recurrent ASCVD events in patients with established coronary disease, with supportive observational data in gout. Methotrexate is associated with fewer cardiovascular events in rheumatoid arthritis (RA), whereas the CIRT trial was neutral in patients without inflammatory arthritis. Hydroxychloroquine has favorable lipid, glycaemic and antithrombotic effects and observational associations with lower cardiovascular risk in RA and systemic lupus erythematosus (SLE), but no definitive cardiovascular outcome trial. Evidence for sulfasalazine is limited and observational, and human data for leflunomide are conflicting. Cardiovascular benefit differs substantially between agents and is most convincing for colchicine in secondary prevention and for inflammation control with methotrexate in RA. Dedicated prospective trials in inflammatory RMD populations are needed before any csDMARD can be prescribed primarily for ASCVD prevention.
引用
- Agca R, Mohamed SS, Popa CD, et al. Cardioprotective mechanisms and efficacy of colchicine, methotrexate, hydroxychloroquine, sulfasalazine and leflunomide in inflammatory rheumatic and musculoskeletal diseases. Rheumatology (Oxford). 2026. PMID: 42920274. doi:10.1093/rheumatology/keag596
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。